MCID: GST105
MIFTS: 44

Gastroesophageal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Adenocarcinoma:

Name: Gastroesophageal Adenocarcinoma 12 15
Gastric and Esophageal Adenocarcinoma 12
Gastro-Esophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080375

Summaries for Gastroesophageal Adenocarcinoma

Disease Ontology : 12 A gastroesophageal cancer that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Gastroesophageal Adenocarcinoma, also known as gastric and esophageal adenocarcinoma, is related to gastric cancer and adenocarcinoma. An important gene associated with Gastroesophageal Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are TGF-Beta Pathway and Actin Nucleation by ARP-WASP Complex. The drugs Fluorouracil and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Gastroesophageal Adenocarcinoma

Diseases related to Gastroesophageal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 gastric cancer 28.9 EGFR ERBB2 MET MTHFR TYMS
2 adenocarcinoma 10.8
3 breast intraductal proliferative lesion 10.2 ERBB2 EGFR
4 breast scirrhous carcinoma 10.2 ERBB2 EGFR
5 progesterone-receptor negative breast cancer 10.2 ERBB2 EGFR
6 breast squamous cell carcinoma 10.2 EGFR ERBB2
7 microglandular adenosis 10.2 ERBB2 EGFR
8 inflammatory breast carcinoma 10.2 ERBB2 EGFR
9 acneiform dermatitis 10.2 ERBB2 EGFR
10 luminal breast carcinoma 10.2 ERBB2 EGFR
11 lipid-rich carcinoma 10.2 EGFR ERBB2
12 doxorubicin induced cardiomyopathy 10.2 MET EGFR
13 mucinous lung adenocarcinoma 10.2 EGFR ERBB2
14 hidradenocarcinoma 10.2 EGFR ERBB2
15 familial renal papillary carcinoma 10.2 EGFR MET
16 mammary paget's disease 10.2 EGFR ERBB2
17 gallbladder adenocarcinoma 10.2 EGFR ERBB2
18 primary peritoneal carcinoma 10.2 EGFR ERBB2
19 adenosquamous lung carcinoma 10.2 EGFR ERBB2
20 pre-malignant neoplasm 10.2 EGFR ERBB2
21 spinal chordoma 10.1 EGFR MET
22 exanthem 10.1 EGFR ERBB2
23 papillary adenocarcinoma 10.1 ERBB2 MST1R
24 in situ carcinoma 10.1 EGFR ERBB2
25 esophageal disease 10.1 EGFR ERBB2
26 breast carcinoma in situ 10.0 EGFR ERBB2 MET
27 stomach disease 10.0 MET ERBB2 EGFR
28 respiratory system cancer 10.0 EGFR ERBB2 MET
29 estrogen-receptor positive breast cancer 10.0 EGFR ERBB2
30 breast ductal carcinoma 10.0 EGFR ERBB2 MET
31 pancreas adenocarcinoma 10.0 MET ERBB2 EGFR
32 penile cancer 10.0 EGFR IFNA2
33 cholangiocarcinoma 10.0 MET ERBB2 EGFR
34 glioblastoma multiforme 10.0 MET ERBB2 EGFR
35 malignant pleural mesothelioma 10.0 MET TYMS
36 hemifacial spasm 10.0 TYMS MTHFR
37 body mass index quantitative trait locus 1 10.0
38 helicobacter pylori infection 10.0 EGFR MET
39 gastric cardia carcinoma 10.0 MTHFR TYMS
40 squamous cell carcinoma, head and neck 9.9 EGFR ERBB2 MET
41 cardia cancer 9.9 MTHFR TYMS
42 transitional cell carcinoma 9.9 IFNA2 ERBB2 EGFR
43 adult acute lymphocytic leukemia 9.9 MTHFR TYMS
44 glioma 9.9 EGFR ERBB2 MET
45 sclerosing cholangitis, neonatal 9.8
46 hemolytic anemia 9.8
47 patulous eustachian tube 9.8
48 lung cancer susceptibility 3 9.8 EGFR ERBB2 MET
49 renal cell carcinoma, nonpapillary 9.8 EGFR IFNA2 MET
50 ductal carcinoma in situ 9.8 EGFR ERBB2

Graphical network of the top 20 diseases related to Gastroesophageal Adenocarcinoma:



Diseases related to Gastroesophageal Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Adenocarcinoma

GenomeRNAi Phenotypes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.89 MST1R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.89 MET
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.89 MST1R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.89 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.89 EGFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.89 EGFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.89 MST1R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.89 MST1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.89 MST1R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.89 MST1R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.89 ERBB2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.89 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.89 MET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.89 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.89 MST1R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.89 MST1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.89 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.89 MET
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.89 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.89 MET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.89 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.89 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.89 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.89 ERBB2 MST1R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.89 MET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.89 EGFR MST1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.89 MST1R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.89 ERBB2 MET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.89 MET
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.89 MST1R
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.89 EGFR ERBB2 MET MST1R
32 Decreased viability with paclitaxel GR00179-A-1 9.33 EGFR ERBB2
33 Decreased viability with paclitaxel GR00179-A-3 9.33 EGFR
34 Increased cell viability after pRB stimulation GR00230-A-1 9.13 EGFR ERBB2 MET

Drugs & Therapeutics for Gastroesophageal Adenocarcinoma

Drugs for Gastroesophageal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
2
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 6857599 5310940 9887054 43805
3
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
4
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1 58-05-9 6006 143
5
Irinotecan Approved, Investigational Phase 4,Phase 2 100286-90-6, 97682-44-5 60838
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
7
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 7440-70-2 271
8 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
9 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
10 Nutrients Phase 4,Phase 3,Phase 2,Phase 1
11 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
12 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
15 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
17 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
18 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
19 Folate Phase 4,Phase 3,Phase 2,Phase 1
20 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Hormones Phase 4,Phase 3,Phase 1,Phase 2
22 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 topoisomerase I inhibitors Phase 4,Phase 2
24 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2
25
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
26
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
27
Cisplatin Approved Phase 2, Phase 3,Phase 3,Early Phase 1 15663-27-1 441203 84093 2767
28
Carboplatin Approved Phase 2, Phase 3 41575-94-4 38904 10339178 498142
29
Epirubicin Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 56420-45-2 41867
30
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1 33069-62-4 36314
31 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
32 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1
33 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
34 Antimitotic Agents Phase 2, Phase 3,Phase 1
35 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
36
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
39
nivolumab Approved Phase 2,Phase 1 946414-94-4
40
Ramucirumab Approved, Investigational Phase 2,Early Phase 1 947687-13-0
41
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
42
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
43
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
44
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 6436030 5284616
46
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
47
Floxuridine Approved Phase 2 50-91-9 5790
48
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
49
Rilotumumab Investigational Phase 2 872514-65-3
50 Antibodies Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
2 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3
3 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3 (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
4 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
5 MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma Unknown status NCT01443065 Phase 2 Oxaliplatin;Folinic Acid;5-fluoro-uracil;panitumumab;AMG102
6 Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma Terminated NCT01182610 Phase 2 Panitumumab;Paclitaxel;Carboplatin;5FU
7 Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Completed NCT01757171 Phase 2 Cabazitaxel
8 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma Completed NCT00390416 Phase 2 Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
9 Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma Completed NCT00816543 Phase 2 DOCETAXEL;S-1;OXALIPLATIN
10 Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma Terminated NCT00667420 Phase 1, Phase 2 panitumumab, epirubicin, oxaliplatin, xeloda
11 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Recruiting NCT02213289 Phase 2
12 A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers Terminated NCT00177255 Phase 2 Docetaxel;Capecitabine
13 Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen Terminated NCT01365130 Phase 2 jevtana
14 FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma Recruiting NCT03528876 Phase 2 FOLFOX and FOLFIRI
15 Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma Completed NCT01932580 Phase 2 FLOT (5-fluorouracil, oxaliplatin, docetaxel)
16 A Study of a Personalized Neoantigen Cancer Vaccine Recruiting NCT03639714 Phase 1, Phase 2
17 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Completed NCT01231399 Phase 1, Phase 2 fluorouracil;leucovorin calcium;oxaliplatin;everolimus
18 First Line Chemotherapy for Advanced Cancer Terminated NCT01980810 Phase 2 albumin-bounded paclitaxel;S-1
19 Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers Terminated NCT00848783 Phase 2 Irinotecan;Cisplatin;Floxuridine;Capecitabine
20 Herzuma-capecitabine/Cisplatin for Gastric Cancer Recruiting NCT03588533 Phase 2 Trastuzumab;Capecitabine;Cisplatin
21 Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer Completed NCT00073502 Phase 2 OSI-7904L
22 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab
23 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Completed NCT01045421 Phase 1, Phase 2 MLN8237 (Alisertib)
24 Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer Active, not recruiting NCT01743365 Phase 2 Cisplatin-5FU-Afatinib
25 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Recruiting NCT02317991 Phase 2 nab-paclitaxel
26 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Not yet recruiting NCT03783936 Phase 2 Oxaliplatin;Leucovorin;5 fluorouracil;Trastuzumab;Avelumab
27 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn NCT02344810 Phase 1, Phase 2 c-Met inhibitor AMG 337;oxaliplatin;leucovorin calcium;fluorouracil
28 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated NCT02551055 Phase 1 MLN1117;TAK-659;Alisertib;Paclitaxel;Docetaxel
29 LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma Active, not recruiting NCT02138929 Phase 1 Everolimus;LDE 225
30 Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer Completed NCT00909025 Phase 1 Claudiximab
31 Study of BAY1834942 in Patients With Solid Tumors Recruiting NCT03596372 Phase 1 BAY1834942;BAY1834942 + Pembrolizumab
32 A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma Recruiting NCT03395847 Early Phase 1 Pembrolizumab
33 Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer Recruiting NCT03784326 Early Phase 1 Atezolizumab;Fluorouracil;Oxaliplatin
34 Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00215514 Early Phase 1 Epirubicin;Cisplatin;5-Fluorouracil (5-FU)
35 Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy Not yet recruiting NCT03613142 Not Applicable
36 A Study for the Production of a Personalized Neoantigen Cancer Vaccine Recruiting NCT03794128

Search NIH Clinical Center for Gastroesophageal Adenocarcinoma

Genetic Tests for Gastroesophageal Adenocarcinoma

Anatomical Context for Gastroesophageal Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Adenocarcinoma:

42
Bone, Lung, Testes, Breast, Brain, Skeletal Muscle, Bone Marrow

Publications for Gastroesophageal Adenocarcinoma

Articles related to Gastroesophageal Adenocarcinoma:

(show top 50) (show all 108)
# Title Authors Year
1
Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. ( 30893708 )
2019
2
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology. ( 30851910 )
2019
3
Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter? ( 30680677 )
2019
4
High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma. ( 30706229 )
2019
5
Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma. ( 29449271 )
2018
6
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. ( 30419350 )
2018
7
Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. ( 30422226 )
2018
8
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. ( 30355278 )
2018
9
Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure? ( 30363693 )
2018
10
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response. ( 29961919 )
2018
11
EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? ( 29858225 )
2018
12
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. ( 29884598 )
2018
13
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. ( 29901103 )
2018
14
Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. ( 29771279 )
2018
15
Customization of therapy for gastroesophageal adenocarcinoma patients. ( 29756119 )
2018
16
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. ( 29674442 )
2018
17
Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. ( 28913947 )
2018
18
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. ( 28978556 )
2018
19
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance. ( 29318901 )
2018
20
Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. ( 29429124 )
2018
21
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. ( 27926778 )
2017
22
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. ( 27530622 )
2017
23
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). ( 28551325 )
2017
24
Update on Gastroesophageal Adenocarcinoma Targeted Therapies. ( 28501091 )
2017
25
PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. ( 27517839 )
2017
26
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. ( 27811012 )
2017
27
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( 25144267 )
2017
28
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. ( 27425578 )
2017
29
PET-CT Post-Hepatic Radiation Changes in Gastroesophageal Adenocarcinoma. ( 27749425 )
2017
30
Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. ( 27770339 )
2017
31
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. ( 27907277 )
2017
32
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. ( 27918764 )
2017
33
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. ( 28129519 )
2017
34
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. ( 28129524 )
2017
35
The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. ( 28306358 )
2017
36
Current status of ramucirumab in gastroesophageal adenocarcinoma. ( 28436242 )
2017
37
Optimal radial force and size for palliation in gastroesophageal adenocarcinoma: a comparative analysis of current stent technology. ( 28444492 )
2017
38
Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. ( 28810883 )
2017
39
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. ( 27836862 )
2017
40
Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. ( 25758761 )
2016
41
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. ( 26628478 )
2016
42
The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. ( 26792144 )
2016
43
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( 27093189 )
2016
44
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. ( 27120436 )
2016
45
Neoadjuvant therapy for gastroesophageal adenocarcinoma. ( 27298768 )
2016
46
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( 27623185 )
2016
47
Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. ( 27726290 )
2016
48
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. ( 27841667 )
2016
49
Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. ( 27965838 )
2016
50
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. ( 28077399 )
2016

Variations for Gastroesophageal Adenocarcinoma

Expression for Gastroesophageal Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Adenocarcinoma.

Pathways for Gastroesophageal Adenocarcinoma

Pathways related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 EGFR ERBB2 IFNA2 MET MST1R
2
Show member pathways
12.64 EGFR ERBB2 MET MST1R
3
Show member pathways
12.63 EGFR ERBB2 IFNA2 MET
4 12.43 EGFR ERBB2 IFNA2 MET
5
Show member pathways
12.31 EGFR ERBB2 MET
6 12.26 EGFR ERBB2 MET
7
Show member pathways
12.24 EGFR ERBB2 MET
8
Show member pathways
12.15 EGFR ERBB2 MET
9
Show member pathways
12.01 EGFR IFNA2 MET
10
Show member pathways
11.97 EGFR ERBB2 MET MST1R
11 11.96 EGFR ERBB2 MET
12
Show member pathways
11.92 EGFR ERBB2 MET
13 11.79 EGFR ERBB2 MET
14 11.43 EGFR ERBB2 MET MST1R
15 11.38 EGFR ERBB2
16 11.36 EGFR ERBB2 MET
17 11.3 KLK6 MST1R
18 11.26 EGFR ERBB2
19 11.25 EGFR ERBB2 MET
20
Show member pathways
11.21 EGFR MET
21 11.17 EGFR MET
22 11.07 EGFR MET
23 11.02 MTHFR TYMS
24 10.81 EGFR ERBB2 MET
25 10.64 EGFR ERBB2 MET MST1R
26 10.42 EGFR ERBB2 MET MST1R

GO Terms for Gastroesophageal Adenocarcinoma

Cellular components related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.26 EGFR ERBB2 MET MST1R
2 basal plasma membrane GO:0009925 8.8 EGFR ERBB2 MET

Biological processes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.87 EGFR ERBB2 MET MST1R
2 protein phosphorylation GO:0006468 9.85 EGFR ERBB2 MET MST1R
3 MAPK cascade GO:0000165 9.76 EGFR ERBB2 MET
4 cell surface receptor signaling pathway GO:0007166 9.71 EGFR ERBB2 IFNA2 MET
5 phosphatidylinositol phosphorylation GO:0046854 9.65 EGFR ERBB2 MET
6 cellular response to growth factor stimulus GO:0071363 9.63 EGFR ERBB2
7 myelination GO:0042552 9.62 ERBB2 KLK6
8 cellular response to epidermal growth factor stimulus GO:0071364 9.61 EGFR ERBB2
9 liver regeneration GO:0097421 9.61 EGFR TYMS
10 ERBB2 signaling pathway GO:0038128 9.6 EGFR ERBB2
11 regulation of cell motility GO:2000145 9.59 EGFR ERBB2
12 positive regulation of phosphorylation GO:0042327 9.58 EGFR IFNA2
13 regulation of ERK1 and ERK2 cascade GO:0070372 9.56 EGFR ERBB2
14 peptidyl-tyrosine phosphorylation GO:0018108 9.56 EGFR ERBB2 MET MST1R
15 positive regulation of MAP kinase activity GO:0043406 9.54 EGFR ERBB2 MST1R
16 hepatocyte growth factor receptor signaling pathway GO:0048012 9.52 MET MST1R
17 tetrahydrofolate interconversion GO:0035999 9.51 MTHFR TYMS
18 tetrahydrofolate metabolic process GO:0046653 9.49 MTHFR TYMS
19 response to folic acid GO:0051593 9.46 MTHFR TYMS
20 positive regulation of protein kinase B signaling GO:0051897 9.46 EGFR ERBB2 MET MST1R
21 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
22 cell differentiation GO:0030154 9.32 EGFR
23 negative regulation of apoptotic process GO:0043066 9.24 EGFR
24 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 EGFR
25 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 8.92 EGFR ERBB2 MET MST1R
26 positive regulation of MAPK cascade GO:0043410 8.65 ERBB2

Molecular functions related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.89 EGFR ERBB2 MET MST1R TYMS
2 kinase activity GO:0016301 9.76 EGFR ERBB2 MET MST1R
3 protein kinase activity GO:0004672 9.73 EGFR ERBB2 MET MST1R
4 nucleotide binding GO:0000166 9.67 EGFR ERBB2 MET TYMS
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 EGFR ERBB2 MET
6 protein phosphatase binding GO:0019903 9.5 EGFR ERBB2 MET
7 Wnt-protein binding GO:0017147 9.48 MET MST1R
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 EGFR ERBB2 MET
9 protein tyrosine kinase activity GO:0004713 9.26 EGFR ERBB2 MET MST1R
10 transmembrane signaling receptor activity GO:0004888 9.16 EGFR ERBB2
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 EGFR ERBB2 MET MST1R

Sources for Gastroesophageal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....